Arrowhead Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. both aim to bring their first wholly owned drugs to market for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), with Ionis’s olezarsen in the leading position. But Arrowhead outlined a new plan to focus all of its late-stage cardiovascular disease development efforts on its FCS and SHTG drug plozasiran, which means the company will seek a partner to pursue Phase III development of its other late-stage cardiovascular candidate, zodasiran.
Key Takeaways
-
Arrowhead will focus on its RNAi drug plozasiran for Phase III development but seek a partner for its other Phase III-ready cardiovascular disease candidate zodasiran.
...
Pasadena, CA-based Arrowhead outlined its Phase III program for plozasiran and revealed its partnering plan for zodasiran during a cardiometabolic research and development review on 25 June. The company reported...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?